Nick Wanliss 0:00
Nick, Hi, I'm Nick Wanliss, head of growth marketing with NOAA medical. NOAA medical is a medical robotics company that helps physicians with the early diagnosis of lung cancer. Lung cancer is a leading cause of death amongst cancers. Lung cancer kills more people each year than colon, breast and prostate combined. Industry thus far has done a poor job delivering technology that clinically, operationally and financially meets the expectations of patients. Lung cancer is so deadly because until the Galaxy system launched, physicians didn't have the tools that they needed to diagnose patients earlier. The majority of lung cancer patients are diagnosed at stage three. Stage Three has a five year survival rate of 36% lung cancer patients have a per patient per month healthcare cost of upwards to $20,000 in the US alone, 250,000 new lung cancer patients are diagnosed each year, either through incidental nodule findings or low dose CT screenings. Unfortunately, only 4% of Medicare eligible patients are being screened. There's a variety of technologies out there that are used to diagnose lung cancer, but unfortunately, they like the ability to diagnose small peripheral nodules, and are able to do it at a price point that allows the facility to utilize it. The Galaxy system is a scalable solution helping with lung cancer management. We have a seamlessly integrated imaging system with a robotic platform. This enables the physician to accurately diagnose lung cancer every time we've removed the barrier of requiring expensive equipment and the staff to manage the scopes, so those dollars and people can be reallocated somewhere else in the facility, we have a clinically, operationally and financially met the requirements and expectations of hospitals as well as physicians and most importantly, the patient. The global lung cancer market size is estimated to be about $70 billion by 2030 there are over 2 million new lung cancer patients diagnosed worldwide each year, and that number only continues to grow. So having a platform like the Galaxy system will help to make an exponential impact, not only on lung cancer diagnosis, but overall treatment of lung cancer with the Galaxy system, we hope, by partnering with physicians, we'll be able to continue to make an impact on patients' lives.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
